ERBB2 and neoplasm: Thus, HER2 positivity was associated with a fourfold and triple negativity with a fivefold higher risk for CNS metastases (HR 4.1, CI 2.06–8.12, p < 0.0001 and HR 5.43, CI 2.81–10.47, p < 0.0001) compared to luminal A-like tumor subtype.